Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study

Manuel Valladares-Ayerbes,Maria José Safont,Encarnación González Flores,Pilar García-Alfonso,Enrique Aranda,Ana-Maria López Muñoz,Esther Falcó Ferrer,Luís Cirera Nogueras,Nuria Rodríguez-Salas,Jorge Aparicio,Marta Llanos Muñoz,Paola Patricia Pimentel Cáceres,Oscar Alfredo Castillo Trujillo,Rosario Vidal Tocino,Mercedes Salgado Fernández,Antonieta Salud-Salvia,Bartomeu Massuti Sureda,Rocio Garcia-Carbonero,Maria Ángeles Vicente Conesa,Ariadna Lloansí Vila,

DOI: https://doi.org/10.1007/s12094-024-03487-4

2024-04-20

Abstract:Abstract Purpose RAS ( KRAS / NRAS ) mutational status on a tumor biopsy is mandatory to guide the best treatment in metastatic colorectal cancer (mCRC). Determining the RAS mutational status by tumor-tissue biopsy is essential in guiding the optimal treatment decision for mCRC. RAS mutations are negative predictive factors for the use of EGFR monoclonal antibodies. Cell-free DNA (cfDNA) analysis enables minimally invasive monitoring of tumor evolution. Methods/patients PERSEIDA was an observational, prospective study assessing cfDNA RAS , BRAF and EGFR mutations (using IdyllaTM) in first-line mCRC, RAS wild-type (baseline tumor-tissue biopsy) patients (cohort 2). Plasma samples were collected before first-line treatment, after 20 ± 2 weeks, and at disease progression. Results 117 patients were included (103 received panitumumab + chemotherapy as first-line treatment). At baseline, 7 (6.8%) patients had RAS mutations, 4 (3.9%) BRAF mutations and no EGFR mutations were detected (cfDNA, panitumumab + chemotherapy subpopulation [panitumumab + Ch]). The baseline RAS mutational status concordance between tissue and liquid biopsies was 94.0% (93.2%, panitumumab + Ch). At 20 weeks, only one patient in the study (included in the panitumumab + Ch) had an emerging cfDNA RAS mutation. No emerging BRAF or EGFR mutations were reported. At disease progression, 6 patients had emergent mutations not present at baseline ( RAS conversion rate: 13.3% [6/45]; 15.0% [6/40], panitumumab + Ch). Conclusions The concordance rate between liquid and solid biopsies at baseline was very high, as previously reported, while our results suggest a considerable emergence of RAS mutations during disease progression. Thus, the dynamics of the genomic landscape in ctDNA may provide relevant information for the management of mCRC patients.

oncology